← Back to all trials
Active Not Recruiting
NCT05866432
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
Conditions: Breast Cancer Stage IV
Sex: All
Ages: 18 Years – 100 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 20
Sponsor: Medical University of Vienna
Location: AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology Vienna
Summary
Datopotamab-deruxtecan in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases.
Eligibility Criteria
Inclusion Criteria:
* Histologically confirmed breast cancer
* Triple-negative disease as defined by immunohistochemistry (IHC) and/or c-erb-B2 gene amplification status. For the definition of hormone-receptor negative disease, a cut-off of \
Source: ClinicalTrials.gov (NCT05866432). StuddyBuddy aggregates publicly available trial information.
